Literature DB >> 26857657

Clinical adherence to thrombophilia screening guidelines at a major tertiary care hospital.

A J Kwon1, M Roshal2, M T DeSancho3.   

Abstract

UNLABELLED: Essentials Thrombophilia screening has significantly increased but has limited clinical utility. We evaluated the positive rate of thrombophilia screening and adherence to published guidelines. Both the positive rate for thrombophilia screening and the adherence to guidelines were low. Guidance implementation is essential to improve current thrombophilia screening practice.
SUMMARY: Background Thrombophilia screening is widely performed but provides limited clinical utility in managing patients predisposed to venous thromboembolism. Although guidelines to limit testing have been published, adherence to those guidelines in the outpatient clinical setting has not been assessed. Objective To evaluate outpatient thrombophilia screening practices at a tertiary academic medical center. Methods We performed a retrospective review of the electronic medical records and a computational analysis of thrombophilia tests collected during a 3-year period (August 2010 to June 2013) at a large teaching hospital. Our primary outcome measures were positive diagnostic yield for thrombophilia and clinician adherence to published thrombophilia screening guidelines in the outpatient setting. Results and Conclusions We found a positive diagnostic yield of 13.8% (95% confidence interval 12.3% to 15.3%) for outpatient thrombophilia screening at our institution. Of the screening tests requiring a second confirmatory assay for definitive diagnosis, only 12% (95% confidence interval 10.3% to 13.7%) were appropriately obtained. We also observed that 73% of patients in our electronic medical record review were inappropriately tested based on existing screening guideline criteria. When parsed by specialty, we identified that hematologists had a higher adherence rate to guideline criteria than do physicians from other specialties. Our study confirms low adherence to thrombophilia screening guidelines across disciplines and indicates the need for continued clinician education.
© 2016 International Society on Thrombosis and Haemostasis.

Entities:  

Keywords:  educational activities; guideline adherence; mass screening; practice guideline; thrombophilia

Mesh:

Year:  2016        PMID: 26857657     DOI: 10.1111/jth.13284

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  5 in total

1.  Do hospital doctors test for thrombophilia in patients with venous thromboembolism?

Authors:  Daryoush Samim; Pedro Marques-Vidal; Lorenzo Alberio; Gérard Waeber; Marie Méan
Journal:  J Thromb Thrombolysis       Date:  2018-08       Impact factor: 2.300

Review 2.  Hypercoagulable States and Thrombophilias: Risks Relating to Recurrent Venous Thromboembolism.

Authors:  Marissa D Rybstein; Maria T DeSancho
Journal:  Semin Intervent Radiol       Date:  2018-06-04       Impact factor: 1.513

3.  Appropriateness of thrombophilia testing in patients in the acute care setting and an evaluation of the associated costs.

Authors:  Riddhi Virparia; Luigi Brunetti; Stuart Vigdor; Christopher D Adams
Journal:  J Thromb Thrombolysis       Date:  2020-01       Impact factor: 2.300

4.  Thrombophilia Impact on Treatment Decisions, Subsequent Venous or Arterial Thrombosis and Pregnancy-Related Morbidity: A Retrospective Single-Center Cohort Study.

Authors:  Kristina Vrotniakaite-Bajerciene; Tobias Tritschler; Katarzyna Aleksandra Jalowiec; Helen Broughton; Justine Brodard; Naomi Azur Porret; Alan Haynes; Alicia Rovo; Johanna Anna Kremer Hovinga; Drahomir Aujesky; Anne Angelillo-Scherrer
Journal:  J Clin Med       Date:  2022-07-19       Impact factor: 4.964

5.  Outpatient Antibiotic Prescription Trends in the United States: A National Cohort Study.

Authors:  Michael J Durkin; S Reza Jafarzadeh; Kevin Hsueh; Ya Haddy Sallah; Kiraat D Munshi; Rochelle R Henderson; Victoria J Fraser
Journal:  Infect Control Hosp Epidemiol       Date:  2018-02-27       Impact factor: 3.254

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.